Targeted therapy is applied in the treatment of advanced primary lung cancer, and the main target of choice is patients with lung adenocarcinoma. The therapeutic drugs usually depend on the results of genetic testing, and can also be combined with chemotherapeutic drugs. Lung adenocarcinoma patients can do genetic test to check whether there is EGFR expression, or ALK or ROS1 gene positive, and if there is a positive result, they can choose the corresponding targeted drugs, such as ositinib mesylate in the case of EGFR gene positivity, and crizotinib in the case of ALK or ROS1 gene positivity. In addition, some anti-vascular targeted drugs, such as bevacizumab, are often used in combination with chemotherapy to improve the efficacy. In the clinic, targeted drugs can be used in combination with chemotherapy drugs, which usually can better prolong the time of tumor progression to the periphery and improve the survival. Some patients with advanced lung cancer cannot tolerate radiotherapy, and if the corresponding gene is positive, they can choose targeted therapy. The most fundamental and important thing of targeted therapy is to clarify the pathological type of patients and conduct genetic testing to choose the corresponding drugs. After targeted therapy, the survival period of some patients increases significantly. Therefore, it is not recommended to give up even in the advanced stage of lung cancer, and corresponding drugs can be chosen, and if the response to the drugs is good, the patient’s condition can be more obviously reversed, and there can be a longer period of remission.